tiprankstipranks
Theralase Technologies (DE:TTX)
FRANKFURT:TTX
Germany Market
TTX
Theralase Technologies
RESEARCH TOOLSreports

Theralase Technologies (TTX) Earnings Dates, Call Summary & Reports

1 Followers

Earnings Data

Report Date
Aug 31, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
>-0.01
Last Year’s EPS
>-0.01
Same Quarter Last Year
Analyst Consensus
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q1 2025
Earnings Call Date:May 29, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call reflects a company at a pivotal moment, with significant progress in clinical studies and plans for expansion into multiple high-value indications. While the financials show a decline in revenue and increased expenses, the strategic initiatives and successful capital raising efforts position Theralase for future growth.
Company Guidance
During the call, Theralase Technologies provided guidance on several metrics and strategic initiatives. The company is on track to complete enrollment in its registrational bladder cancer study by summer 2025, with a 15-month patient follow-up expected to conclude by the third quarter of 2026. Theralase plans to file a New Drug Application with Health Canada and the FDA in the fourth quarter of 2026, aiming for marketing approval in early 2027. Financially, the company reported nominal revenues of $91,000 for Q1 2025, largely from its Cool Laser Therapy systems, down from $175,000 the previous year. Despite a net loss of $1.47 million, Theralase has raised nearly $7.5 million over the past 24 months through private placements. The company is exploring a potential U.S. uplist and institutional financing, which could enhance its capital position and broaden its investor base. Additionally, Theralase is advancing a pipeline that includes nine new indications, with plans for Phase I/II clinical studies in 2026. The company highlighted a 62% complete response rate in its bladder cancer study, emphasizing the safety and efficacy of its Ruvidar treatment.
Completion of Bladder Cancer Study Enrollment
Theralase is on track to complete enrollment in a critical bladder cancer study by the summer of 2025, marking a significant milestone in their clinical development.
Expansion into New Oncology and Virology Indications
Theralase plans to expand its pipeline into 9 high-value indications, including brain cancer, lung cancer, pancreatic cancer, and Herpes Simplex virus, positioning the company for growth in these areas.
Strong Interim Clinical Results
Study II for bladder cancer achieved a 62% complete response rate at any time, with no serious adverse events related to the treatment, indicating a promising safety and efficacy profile.
Potential U.S. Listing and Institutional Raise
Theralase is exploring a U.S. institutional raise and listing, which could broaden the investor base, improve stock liquidity, and provide necessary capital for pipeline expansion.
Successful Capital Raising
Theralase successfully closed private placements totaling $730,000 in the first and second quarters of 2025, contributing to nearly $7.5 million raised over the past 24 months.

Theralase Technologies (DE:TTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

DE:TTX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 31, 2026
2026 (Q2)
>-0.01 / -
-0.002―――
May 29, 2026
2026 (Q1)
- / -
-0.004―――
May 04, 2026
2025 (Q4)
>-0.01 / >-0.01
-0.00433.33% (<+0.01)――
Nov 10, 2025
2025 (Q3)
>-0.01 / >-0.01
-0.0020.00% (0.00)――
Aug 26, 2025
2025 (Q2)
>-0.01 / >-0.01
-0.00320.00% (<+0.01)――
May 29, 2025
2025 (Q1)
>-0.01 / >-0.01
-0.0040.00% (0.00)――
Mar 12, 2025
2024 (Q4)
>-0.01 / >-0.01
0―――
Nov 27, 2024
2024 (Q3)
>-0.01 / >-0.01
0―――
Aug 12, 2024
2024 (Q2)
>-0.01 / >-0.01
0―――
May 30, 2024
2024 (Q1)
0.00 / >-0.01
-0.00640.00% (<+0.01)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DE:TTX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 29, 2026
€0.13€0.13-0.78%
May 04, 2026
€0.18€0.17-5.95%
Nov 10, 2025
€0.10€0.11+1.92%
Aug 26, 2025
€0.11€0.12+9.17%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Theralase Technologies (DE:TTX) report earnings?
Theralase Technologies (DE:TTX) is schdueled to report earning on Aug 31, 2026, TBA (Confirmed).
    What is Theralase Technologies (DE:TTX) earnings time?
    Theralase Technologies (DE:TTX) earnings time is at Aug 31, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Theralase Technologies stock?
          The P/E ratio of Theralase Technologies is N/A.
            What is DE:TTX EPS forecast?
            DE:TTX EPS forecast for the fiscal quarter 2026 (Q2) is >-0.01.